Pulmonx (LUNG) Other Non-Current Liabilities (2019 - 2022)
Pulmonx (LUNG) reported Other Non-Current Liabilities of $179000.0 for Q2 2022, little changed on a QoQ basis from $179000.0 in Q1 2022.
Pulmonx (LUNG) has 4 years of Other Non-Current Liabilities data on file, last reported at $179000.0 in Q2 2022.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $179000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $179000.0 (changed N/A YoY) and the FY2021 annual result came in at $179000.0, changed N/A from the prior year.
- Other Non-Current Liabilities steadied at $179000.0 in Q2 2022 per LUNG's latest filing, from $179000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.9 million in Q3 2020 and bottomed at $179000.0 in Q4 2021.
- The 4-year median for Other Non-Current Liabilities is $179000.0 (2021), against an average of $720400.0.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pulmonx | 67.30 Mn | -2.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 179,000.00 |
| Mar 31, 2022 | 179,000.00 |
| Dec 31, 2021 | 179,000.00 |
| Sep 30, 2020 | 1.90 Mn |
| Dec 31, 2019 | 1.17 Mn |